Ehave has entered into a Multi-Tier Global Partnership with MyLifeID that will allow individuals to carry their health and mental health records with them at all times. The U. S. Department of Health ...

Ehave signed a Letter of Intent to acquire 100% of PsychedeliTech, an incubator and discovery platform to elevate psychedelic medicine Psychedeli-Tech prepares to lead in the commercialization of ...

AIHeadHunter Slashes Hiring Time by 85% and Costs by 70% — Ehave’s Vision to Incubate Scalable Platforms Tackling Real-World Inefficiencies Comes to Life in a $700 Billion Industry Projected to Top $2 ...

Ehave will partner with Brain Scientific Inc. to leverage both data and AI to correlate biomarkers for the Identification of Chronic pain, Depression (major and persistent), PTSD, Bipolar disorder, ...

MIAMI, Aug. 11, 2021 (GLOBE NEWSWIRE) -- Ehave, Inc., (OTC Pink: EHVVF) (the “Company”), a provider of digital therapeutics for the psychedelic and mental health sectors, announced today it has ...

MIAMI, June 03, 2021 (GLOBE NEWSWIRE) -- Ehave, Inc. (OTC Pink: EHVVF) (the “Company”), a provider of digital therapeutics delivering evidence-based therapeutic interventions to patients, announced ...

Ehave, Inc. to leverage data and AI to correlate biomarkers for the identification of psychedelic drug administration as a treatment for Chronic pain, Depression (major and persistent), PTSD, Bipolar ...

Ehave's Bioinformatics Platform Technology to Be Used to Evaluate Aequus' Products in Multiple Neurological Disorders VANCOUVER, March 5, 2018 /CNW/ - Aequus Pharmaceuticals Inc. (TSX-V: AQS) (OTCQB: ...

Dr. Braunstein is recognized worldwide in Psychedelic Psychiatry, which entails treating psychiatric disorders with psychedelics MIAMI, FL / ACCESSWIRE / March 27, 2020 / Ehave, Inc., (OTC PINK:EHVVF) ...

Proprietary computer vision technology will provide the Ehave Dashboard and Ehave Medical App with the ability to extract information about changes in light absorption on an individual’s facial skin ...